2122 J ournal of Medicinal Chemistry, 1997, Vol. 40, No. 14
Communications to the Editor
(4) Furr, B. J .; J ordan, V. C. The pharmacology and clinical uses of
tamoxifen. Pharmacol. Ther. 1984, 25, 127-205. (b) McNab, M.
W.; Tallarida, R. J .; J oseph, R. An evaluation of tamoxifen as a
partial agonist by classical receptor theory, an explanation of
the dual action of tamoxifen. Eur. J . Pharmacol. 1984, 103, 321-
326. (c) Poulin, R.; Me´rand, Y.; Poirier, D.; Le´vesque, C.; Dufour,
J .-M.; Labrie, F. Antiestrogenic properties of keoxifene, trans-
4-hydroxytamoxifen and ICI 164384, a new steroidal antiestro-
gen, in ZR-75-1 human breast cancer cells. Breast Cancer Res.
Treat. 1989, 14, 65-76.
Me´rand, Y.; Labrie, F. Effect of 24-week treatment with the
antiestrogen EM-800 on estrogen-sensitive parameters in intact
and ovariectomized mice. Proceedings of the 10th International
Congress of Endocrinology, San Francisco, 1996, Abstract P1-
68, p 151. (c) Couillard, S.; Labrie, C.; Gauthier, S.; Labrie, F.
Inhibitory effect of a new non-steroidal pure antiestrogen (EM-
800) in combination with DHEA on human ZR-75-1 breast
tumors in nude mice. Proceedings of the 8th International
Congress on the Menopause, Sydney, Australia, 1996, Abstract
F120, p 80. (d) Grese, T. A.; Sluka, J . P.; Bryant, H. U.; Cole, H.
W.; Kim, J . R.; Magee, D. E.; Rowley, E. R.; Sato, M. Benzopyran
selective estrogen receptor modulators (SERMS): pharmacologi-
cal effects and structural correlation with Raloxifene. Bioorg.
Med. Chem. Lett. 1996, 6, 903-908. (e) Tremblay, G. B.;
Tremblay, A.; Copeland, N. G.; Gilbert, D. J .; J enkins, N. A.;
Labrie, F.; Giguere, V. Cloning, chromosomal Localization and
Functional Analysis of the Murine Estrogen Receptor â. Mol.
Endocrinol. 1997, 11, 353-365.
(5) (a) Wakeling, A. E.; Bowler, J . Biology and mode of action of
pure antioestrogens. J . Steroid Biochem. 1988, 30, 141-147. (b)
Wakeling, A. E.; Dukes, M.; Bowler, J . A potent specific pure
antiestrogen with clinical potential. Cancer Res. 1991, 51, 3867-
3873. (c) Wakeling, A. E.; Bowler, J . ICI 182,780,
a new
antioestrogen with clinical potential. J . Steroid Biochem. Mol.
Biol. 1992, 43, 173-177. (d) de Launoit, Y.; Dauvois, S.; Dufour,
M.; Simard, J .; Labrie, F. Inhibition of cell cycle kinetics and
proliferation by the androgen 5R-dihydrotestosterone and anti-
estrogen N,n-butyl-N-methyl-11-[16′R-chloro-3′,17â-dihydroxy-
estra-1′,3′,5′-(10′)trien-7′R-yl]undecanamide in human breast
cancer ZR-75-1 cells. Cancer Res. 1991, 51, 2797-2802. (e)
Le´vesque, C.; Me´rand, Y.; Dufour, J . M.; Labrie, C.; Labrie, F.
Synthesis and biological activity of new halo-steroidal anties-
trogens. J . Med. Chem. 1991, 34, 1624-1630. (f) Labrie, C.;
Martel, C.; Dufour, J .-M.; Le´vesque, C.; Me´rand, Y.; Labrie, F.
Novel compounds inhibit estrogen formation and action. Cancer
Res. 1992, 52, 610-615.
(15) (a) Gottardis, M. M.; Robinson, S. P.; Satyaswaroop, P. G.;
J ordan, V. C. Contrasting actions of tamoxifen on endometrial
and breast tumor growth in the athymic mouse. Cancer Res.
1988, 48, 812-815. (b) Chalbos, D.; Philips, A.; Galtier, F.;
Rochefort, H. Synthetic antiestrogens modulate induction of pS2
and cathepsin-D messenger ribonucleic acid by growth factors
and adenosine 3′,5′-monophosphate in MCF7 cells. Endocrinol-
ogy 1993, 133, 571-576. (c) Yang, N. N.; Venugopalan, M.;
Hardikar, S.; Glasebrook, A. Identification of an estrogen
response element activated by metabolites of 17â-estradiol and
raloxifene. Science 1996, 273, 1222-1225. (d) Chetrite, G.;
Pasqualini, J . R. Biological responses of ICI 164,384 and other
antioetrogens in vaginal and uterine cells of fetal guinea pig in
culture. Acta Endocrinol. 1991, 125, 401-408. (e) Giambiagi,
N.; Pasqualini, J . R. Studies on the activation of the oestrogen
receptor bound to the anti-oestrogens 4-hydroxytamoxifen and
ICI 164,384 by using three monoclonal antibodies. J . Mol.
Endocrinol. 1991, 7, 9-19. (f) Weaver, C. A.; Springer, P. A.;
Katzenellenbogen, B. S. Regulation of pS2 gene expression by
affinity labeling and reversibly binding estrogens and anti-
estrogens: Comparison of effects on the native gene and on pS2-
chloramphenicol acetyltransferase fusion genes transfected into
MCF-7 human breast cancer cells. Mol. Endocrinol. 1988, 2,
936-945.
(16) (a) Rutqvist, L. E.; J ohansson, H.; Signomklao, T.; J ohansson,
U.; Fornander, T.; Wilking, N. Adjuvant tamoxifen therapy for
early stage breast cancer and second primary malignancies. J .
Natl. Cancer Inst. 1995, 87, 645-651. (b) Fornander, T.; Hell-
stro¨m, A.-C.; Moberger, B. Descriptive clinicopathologic study
of 17 patients with endometrial cancer during or after adjuvant
tamoxifen in early breast cancer. J . Natl. Cancer Inst. 1993, 85,
1850-1855.
(17) Sanchez, R.; Simard, J .; Poirier, D.; Gauthier, S.; Singh, S. M.;
Me´rand, Y.; Labrie, F. Pure antiestrogenic activity of EM-139
and EM-800 in human endometrial adenocarcinoma Ishikawa
cells. Proceedings of the 10th International Congress of Endo-
crinology, San Francisco, 1996, Abstract P1-80, p 154.
(6) Wa¨ha¨la¨, K.; Hase, T. A. Expedient synthesis of polyhydroxy-
isoflavones. J . Chem. Soc., Perkin Trans. 1 1991, 3005-3008.
(7) Chromatographed chromanones 5 (∼5:1 trans/cis ratio) contain
about 15% of the corresponding Z-chalcone.
(8) Salts (S)-7 can be recrystallized once more to increase diaster-
eomeric excess.
(9) The optical rotations of compounds (S)-1 and (R)-1 are [R]24
D
95° (c 1.0, CH2Cl2) and [R]24 -94° (c 1.0, CH2Cl2), respectively.
D
(10) (a) Asselin, J .; Me´lanc¸on, R.; Moachon, G.; Be´langer, A. Char-
acteristics of binding to estrogen, androgen, progestin, and
glucocorticoid receptors in 7,12-dimethylbenz[a]anthracene-
induced mammary tumors and their hormonal control. Cancer
Res. 1980, 40, 1612-1622. (b) Cheng, Y. C.; Prusoff, W. H.
Relationship between the inhibition constant (Ki) and the
concentration of inhibitor which causes 50 per cent inhibition
(IC50) on an enzymatic reaction. Biochem. Pharmacol. 1973, 22,
3099-3108. (c) The apparent inhibition constant Ki values were
calculated according to the following equation: Ki ) IC50/(1 +
S/K) where S represents the concentration of labeled E2 and K
is the KD value of E2 (0.14 nM) for the estrogen receptor. RBA
values were calculated as follows: RBA ) (IC50 of E2)/(IC50 of
tested compound) × 100.
(11) Labrie, F.; Leblanc, G.; Gauthier, S.; Singh, S. M.; Provencher,
L.; Li, X.; Me´rand, Y. Binding characteristics of the pure
antiestrogens EM-652 and EM-800 to the human estrogen
receptor. Proceedings of the 10th International Congress of
Endocrinology, San Francisco, 1996, Abstract P2-801, p 605.
(12) (a) Simard, J .; Dauvois, S.; Haagensen, D. E.; Le´vesque, C.;
Me´rand, Y.; Labrie, F. Regulation of progesterone-binding breast
cyst protein GCDFP-24 secretion by estrogens and androgens
in human breast cancer cells: a new marker of steroid action in
breast cancer. Endocrinology 1990, 126, 3223-3231. (b) Keydar,
I.; Chen, L.; Karby, S.; Weiss, F. R.; Delarea, J .; Radu, M.;
Chaitcik, S.; Brenner, H. J . Establishment and characterization
of a cell line of human breast carcinoma origin. Eur. J . Cancer
1979, 15, 659.
(13) Simard, J .; Labrie, C.; Be´langer, A.; Gauthier, S.; Singh, S. M.;
Me´rand, Y.; Labrie, F. Characterization of the effects of the novel
antiestrogen EM-800 on basal and estrogen-induced proliferation
of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro.
Int. J . Cancer, in press.
(14) (a) Martel, C.; Gauthier, S.; Me´rand, Y.; Li, X.; Provencher, L.;
Labrie, F. Comparison of the effects of the new antiestrogens
EM-800 and ICI 182 780 on estrogen-sensitive parameters in
the ovariectomized mouse. Proceedings of the 10th International
Congress of Endocrinology, San Francisco, 1996, Abstract P1-
72, p 152. (b) Luo, S.; Sourla, A.; Be´langer, A.; Gauthier, S.;
(18) Littlefield, B. A.; Gurpide, E.; Markiewicz, L.; McKinley, B.;
Hochberg, R. B. A simple and sensitive microtiter plate estrogen
bioassay based on stimulation of alkaline phosphatase in Ish-
ikawa cells: estrogenic action of ∆5 adrenal steroids Endocrinol-
ogy 1990, 127, 2757-2762.
(19) (a) Saeed, A.; Sharma, A. P.; Durani, N.; J ain, R.; Durani, S.;
Kapil, R. S. Structure-activity relationship of antiestrogens.
Studies on 2,3-diaryl-1-benzopyrans. J . Med. Chem. 1990, 33,
3210-3216. (b) Sharma, A. P.; Saeed, A; Durani, S.; Kapil, R.
S. Structure-activity relationship of antiestrogens. Effect of the
side chain and its position on the activity of 2,3-diaryl-2H-1-
benzopyrans. J . Med. Chem. 1990, 33, 3216-3222. (c) Sharma,
A. P.; Saeed, A; Durani, S.; Kapil, R. S. Structure-activity
relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-
2H-1-benzopyrans. J . Med. Chem. 1990, 33, 3222-3229.
(20) von Angerer, E. The estrogen receptor as a target for rational
drug design. In Molecular biology intelligence unit; R. G. Landes
Company: Austin, 1995; pp 67-69.
J M970095O